Does clinical trial liability insurance cover investigator-sponsors and clinical sites?

Clinical trial liability (CTL) insurance is purpose-built for the human-subject research exposure: bodily injury or death of a clinical trial subject caused by the investigational drug, device, or trial procedures. The named insured is typically the sponsor IND-holder (the entity that filed the Investigational New Drug application with the FDA), and the policy covers the sponsor's liability arising from the trial.

A standard CTL policy automatically extends coverage to (1) the named sponsor entity, (2) its subsidiaries and affiliates, and (3) directors, officers, and employees acting within the scope of their duties. It does not automatically cover separately-contracted parties — investigators, sites, CROs, or contract laboratories — unless those parties are added as additional insureds.

An "investigator-sponsor" or "investigator-initiated study" (IIS) inverts the standard sponsor relationship: an individual investigator (typically at an academic medical center) holds the IND and runs the trial, often with financial or in-kind support from a pharmaceutical sponsor that does not hold the IND itself.

In an IIS structure, the investigator-sponsor needs its own clinical trial liability coverage as the IND-holder. The supporting pharma sponsor sometimes provides this coverage as a contractual obligation under the IIS support agreement; sometimes the investigator-sponsor (or the academic medical center) maintains its own CTL policy. The arrangement varies and should be explicit in the IIS support agreement.

Clinical sites — hospitals, academic medical centers, contract research clinics — typically have their own professional liability and general liability covering the site's acts and omissions. The clinical trial sponsor extends additional-insured wording to the site for the trial activity, usually via the clinical trial agreement (CTA) and the sponsor's CTL policy.

The friction point is the scope of the AI wording. Sponsors typically extend AI for claims arising from the sponsor's acts (the investigational product itself, sponsor protocol, sponsor-provided materials). They do not extend AI for the site's own acts (clinical care delivered by site staff, deviation from sponsor protocol caused by site error). The boundary is in the CTA.

CROs sit in between. The sponsor-CRO master services agreement (MSA) typically requires the CRO to maintain professional liability and E&O for the CRO's services, and to name the sponsor as additional insured. The sponsor in turn typically names the CRO as additional insured on the sponsor's CTL policy for the trial activity.

The result is a mutual AI structure: the CRO's E&O covers CRO errors with the sponsor as AI; the sponsor's CTL covers the investigational product with the CRO as AI. Each party's policy responds to the exposure it best understands.

For sponsor-led trials, verify that the CTA explicitly names the site as additional insured under the sponsor's CTL policy and that the scope of the AI is appropriate to the trial (covers investigational product, sponsor protocol, sponsor-provided materials).

For investigator-initiated studies, verify which entity is the IND-holder and which entity maintains the CTL policy. If the sponsor pharmaceutical company is providing the CTL coverage, verify that the IIS support agreement explicitly says so and that the investigator-sponsor is the named insured.

For CRO arrangements, verify the mutual AI structure and that the policy limits are sized to the trial. A typical Phase II/III trial requires $5M-$25M CTL depending on subject count and indication severity.